|
Originally published In Press as doi:10.1074/jbc.M302425200 on April 21, 2003
J. Biol. Chem., Vol. 278, Issue 28, 26007-26014, July 11, 2003
Structural and Biochemical Evidence for an Autoinhibitory Role for Tyrosine 984 in the Juxtamembrane Region of the Insulin Receptor*
Shiqing Li,
Nicole D. Covino,
Evan G. Stein,
Jeffrey H. Till and
Stevan R. Hubbard
From the
Skirball Institute of Biomolecular Medicine and Department of
Pharmacology, New York University School of Medicine, New York, New York
10016
Tyrosine 984 in the juxtamembrane region of the insulin receptor, between
the transmembrane helix and the cytoplasmic tyrosine kinase domain, is
conserved among all insulin receptor-like proteins from hydra to humans.
Crystallographic studies of the tyrosine kinase domain and proximal
juxtamembrane region reveal that Tyr-984 interacts with several other
conserved residues in the N-terminal lobe of the kinase domain, stabilizing a
catalytically nonproductive position of -helix C. Steady-state kinetics
measurements on the soluble kinase domain demonstrate that replacement of
Tyr-984 with phenylalanine results in a 4-fold increase in
kcat in the unphosphorylated (basal state) enzyme.
Moreover, mutation of Tyr-984 in the full-length insulin receptor results in
significantly elevated receptor phosphorylation levels in cells, both in the
absence of insulin and following insulin stimulation. These data demonstrate
that Tyr-984 plays an important structural role in maintaining the quiescent,
basal state of the insulin receptor. In addition, the structural studies
suggest a possible target site for small molecule activators of the insulin
receptor, with potential use in the treatment of noninsulin-dependent diabetes
mellitus.
Received for publication, March 10, 2003
, and in revised form, April 14, 2003.
The atomic coordinates and structure factors (code 1P14) have been
deposited in the Protein Data Bank, Research Collaboratory for Structural
Bioinformatics, Rutgers University, New Brunswick, NJ
(http://www.rcsb.org/).
* This work was supported by National Institutes of Health Grant DK52916 (to
S. R. H.). Financial support for Beamline X12C of the National Synchrotron
Light Source comes principally from the National Institutes of Health and the
Department of Energy. The costs of publication of this article were defrayed
in part by the payment of page charges. This article must therefore be hereby
marked "advertisement" in accordance with 18 U.S.C.
Section 1734 solely to indicate this fact.
Present address: Exelixis, Inc., South San Francisco, CA 94083.
To whom correspondence should be addressed: Skirball Institute of Biomolecular
Medicine, New York University School of Medicine, 540 First Ave., New York, NY
10016. Tel.: 212-263-8938; Fax: 212-263-8951; E-mail:
hubbard{at}saturn.med.nyu.edu.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
P. P. Knowles, J. Murray-Rust, S. Kjaer, R. P. Scott, S. Hanrahan, M. Santoro, C. F. Ibanez, and N. Q. McDonald
Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain
J. Biol. Chem.,
November 3, 2006;
281(44):
33577 - 33587.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. D. Mol, D. R. Dougan, T. R. Schneider, R. J. Skene, M. L. Kraus, D. N. Scheibe, G. P. Snell, H. Zou, B.-C. Sang, and K. P. Wilson
Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase
J. Biol. Chem.,
July 23, 2004;
279(30):
31655 - 31663.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2003 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|